. . . . . "Olanzapine" . . . "alcohol use disorder" . . . . . . "Olanzapine was FDA approved for the treatment of schizophrenia and bipolar disorder only. It is an atypical antagonist of D2 and D4 receptors which determines a decrease in craving for alcohol. The DRD4 gene of dopamine presents a VNTR polymorphism, with a number of repetitions that varies from 2 to 11 which allows for the division of individuals in two subgroups: those with a number of repetitions between 2 and 6, classified as DRD4 S and those with more than 7 repetitions, classified as DRD4 L. Association studies between this variation and AUD have showed that individuals who carry the L allele exhibit greater craving after alcohol intake,50. Another study has investigated the association olanzapine-DRD4 showing that olanzapine reduces craving to the L allele carriers only, while no benefits were observed in S allele carriers." . . . . . . . "adults" . . . "RSA" . "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCR9fz0fKCdWOWC+pxhkQhEM/ppbdIYe5TLSdj+lJzSlv9mYBaPgrzVezSwwbmhlHBPDZa4/vHycU315BdmUGq+pXllp9+rWFfrb+kBJwhZjpG6BeyyXBsRFz4jmQVxl/ZYHilQTh/XalYzKkEAyTiEMPee4Kz61PaWOKH24CsnOQIDAQAB" . "EZH5DT4K3l3uk6H65DHWAFQwIG+q31cWFOWWvUTRFQEbfkP87pLflbnQY7oS7uK9Y2L1/1z7o1EAR8ztBHhZBiyhtO0V2nHq+BNRb4bTQw5R6rSh7tLcxWc0nWl4tfQKmTRJFa/E1ZlhMXlourWMY1+X7ekIYjn7T3WtuTCDpnQ=" . . "2022-09-16T11:54:35.529379"^^ . . . "2.3.0" .